The Pupil Diameter as a Possible Indicator of Neurodegenerative Diseases and Response to Acetylcholinesterase Inhibitors Therapy: In-Depth Measurements Following Topical Administration of Tropicamide and Pilocarpine.
Alzheimer’s disease
acetylcholinesterase inhibitors
mydriatic agents
vascular dementia
Journal
American journal of Alzheimer's disease and other dementias
ISSN: 1938-2731
Titre abrégé: Am J Alzheimers Dis Other Demen
Pays: United States
ID NLM: 101082834
Informations de publication
Date de publication:
Historique:
entrez:
3
9
2020
pubmed:
3
9
2020
medline:
11
2
2021
Statut:
ppublish
Résumé
The aim of this study is to assess whether pupillary modifications following ocular anticholinergic and cholinergic drugs can identify subjects with neurodegenerative diseases from early stages. 51 subjects were divided into 3 groups, according to different neurodegenerative diseases, and compared with a control group of 10 patients. Pupil diameter has been measured at different times after topical administration of tropicamide 0.01% in the right eye. Then, topical administration of pilocarpine 0.06% has been performed, followed by pupillary constriction measurement. Pupillary response rates were stratified according to acetylcholinesterase inhibitors intake. Observed mydriasis and pupillary constriction was similar in all study groups at all evaluation times. Patients without acetylcholinesterase inhibitors intake presented greater mydriasis. Although it was not possible to observe significant differences among groups in terms of pupillary response, the analysis of pupillary features may become an useful tool to detect efficacy of acetylcholinesterase inhibitors.
Sections du résumé
BACKGROUND
The aim of this study is to assess whether pupillary modifications following ocular anticholinergic and cholinergic drugs can identify subjects with neurodegenerative diseases from early stages.
METHODS
51 subjects were divided into 3 groups, according to different neurodegenerative diseases, and compared with a control group of 10 patients. Pupil diameter has been measured at different times after topical administration of tropicamide 0.01% in the right eye. Then, topical administration of pilocarpine 0.06% has been performed, followed by pupillary constriction measurement. Pupillary response rates were stratified according to acetylcholinesterase inhibitors intake.
RESULTS
Observed mydriasis and pupillary constriction was similar in all study groups at all evaluation times. Patients without acetylcholinesterase inhibitors intake presented greater mydriasis.
CONCLUSIONS
Although it was not possible to observe significant differences among groups in terms of pupillary response, the analysis of pupillary features may become an useful tool to detect efficacy of acetylcholinesterase inhibitors.
Identifiants
pubmed: 32875808
doi: 10.1177/1533317520951693
doi:
Substances chimiques
Cholinesterase Inhibitors
0
Pilocarpine
01MI4Q9DI3
Tropicamide
N0A3Z5XTC6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM